Consistent with this conclusion, PPTP/C testing of the pan-PI3K inhibitor pilaralisib (SAR245408) did not show objective responses in 7 ALL models (Table 7) (Reynolds et al., 2013). Here, PIK3CA is linked to acute lymphoblastic leukemia.